JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007. References: Di Fiore A, De Simone G, Alterio V, Riccio V, Winum JY, Carta F, Supuran CT. The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies. Org Biomol Chem. 2016 Jun 7;14(21):4853-8. doi: 10.1039/c6ob00803h. Epub 2016 May 6. PubMed PMID: 27151329.

纯度：≥98%

CAS：877316-38-6